The impact of remibrutinib on urticaria control in patients with chronic spontaneous urticaria: Long-term results from the REMIX-1/-2 phase 3 trials

M. Metz, B. Yang, E. Boren, H. Takahashi, S. Altrichter, P. Wang, K. Lheritier, El-D. Martzloff, S. Haemmerle, S. Saini

Please click <u>HERE</u> to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this <u>LINK</u> to access the abstract after February 28, 2025, once it is available at the congress website

💥 AAAAI/WAO Joint Congress 2025, American Academy of Allergy, Asthma & Immunology (AAAAI) and World 💢 Allergy Organization (WAO), February 28 — March 3, 2025